Anna Körner

Anna Körner

Auto-generated profile, based on publicly available information

Anna Körner

Universität Bremen

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Journal of Diabetes Science and Technology
Verified
Journal Article
Open access
PDF file
OCOhad Cohen
Ohad Cohen
AKAnna Körner
Anna Körner
RCRudolf Chlup
Rudolf Chlup
CZChristos S. Zoupas
Christos S. Zoupas
ARAnton K. Ragozin
Anton K. Ragozin
AVAndriani Vazeou
Andriani Vazeou
Conducted by highly experienced investigators with abundant time and resources, phase III studies of continuous glucose sensing (CGS) may lack generalizability to everyday clinical practice. Community or academic practices in six Central and Eastern European or Mediterranean countries prospectively established an anonymized registry of consecutive patients with type 1 insulin-dependent diabetes mellitus starting CGS-augmented insulin pump therapy with the Paradigm® X22 (Medtronic MiniMed, Northridge, CA) under everyday conditions, without prior CGS with another device. We compared glycosylated hemoglobin (GHb) values before and after 3 months of CGS and assessed relationships between insulin therapy variables and glycemia-related variables at weeks 1, 4, and 12 of CGS. Of 102 enrolled patients, 85 (83%) with complete weeks 1, 4, and 12 sensor data and baseline/3-month GHb data were evaluable. Evaluable patients were ∼54% male and ∼75% adult (mean age, 33.2 ± 16.9 years) with longstanding diabetes and high personal/family education levels. Mean GHb declined significantly after 3 months of CGS (7.55 ± 1.33% at baseline to 6.81 ± 1.08% after 12 weeks, 0.74% absolute decrease, P < 0.001). The absolute GHb reduction correlated significantly (P < 0.0005) with baseline GHb: larger absolute reductions tended to occur when baseline levels were higher. An increased basal insulin dose as a percentage of the total daily insulin dose and a decreased daily bolus count from week 1 to week 12 of CGS predicted GHb improvement from baseline to week 12. CGS-augmented insulin pump therapy appears to improve glycemic control in type 1 diabetes in varied everyday practice settings.

1 March 2026 in Mathematical Thinking and Learning
Verified
Journal Article
Open access
AKAnna Körner
Anna Körner
DBDagmar Bönig
Dagmar Bönig

1 January 2021 in Diabetologia Hungarica
Verified
Journal Article
Open access
JÉJúlia Érdi
Júlia Érdi
AVAdrienn Vatamány-Einbeck
Adrienn Vatamány-Einbeck
ÁNÁgota Nyírő
Ágota Nyírő
VHVivien Herczeg
Vivien Herczeg
ALAndrea Luczay
Andrea Luczay
PTPéter Tõth-Heyn
Péter Tõth-Heyn

1 January 2021 in Diabetologia Hungarica
Verified
Journal Article
Open access
ZZZalán Zelena
Zalán Zelena
Dóra ZelenaDóra Zelena
Dóra Zelena
AKAnna Körner
Anna Körner

1 January 2021 in Diabetologia Hungarica
Verified
Journal Article
Open access
VHVivien Herczeg
Vivien Herczeg
EHEszter Hámory
Eszter Hámory
EMEszter Muzslay
Eszter Muzslay
PTPéter Tõth-Heyn
Péter Tõth-Heyn
AKAnna Körner
Anna Körner
ALAndrea Luczay
Andrea Luczay

29 August 2023 in Atherosclerosis
Verified
Journal Article
Open access
PSPaulina Elena Stürzebecher
Paulina Elena Stürzebecher
MSM. Schlingmann
M. Schlingmann
KUKonstantin Lukas Uttinger
Konstantin Lukas Uttinger
MVMandy Vogel
Mandy Vogel
Uta CeglarekUta Ceglarek
Uta Ceglarek
ULU. Laufs
U. Laufs